close

Geron Corporation, a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. The company develops a range of anti-cancer therapies, including anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines, as well as focuses on the development of products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring, and screening. Its products include GRN163 and GRN163L, which are telomerase inhibitors for the treatment of chronic lymphoproliferative diseases, solid tumors, non-small cell-lung cancer, breast cancer, and multiple myeloma, which are in Phase I trials; and GRNVAC1, a telomerase cancer vaccine that is in Phase II clinical trial for the treatment of acute myelogenous leukemia. Geron Corporation also develops human embryonic stem cell-based therapeutics, with its spinal cord injury treatment. The company has research, development, and commercialization license agreement with Merck & Co., Inc. to use telomerase in non-dendritic cell cancer vaccines; and a license agreement with Sienna Cancer Diagnostics to detect telomerase for in vitro cancer diagnosis. Geron Corporation was founded in 1990 and is based in Menlo Park, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	1.72
Volume	537074
Volume Avg	(mio) 1.26
52 Week High	5.24
52 Week Low	1.35
PE	N/A
PE (group average)	39
EPS Year	-0.78
EPS change Q/Q	-66.1%
EPS change Q/Q Yr ago	-11.11%
EPS change Q/Q next Q est	-33.33%
EPS change Y/Y	-32.76%
REV change Q/Q	36.36%
REV change Q/Q Yr ago	66.67%
EPS next Q est	-0.15
EPS next Y est	-0.69
Divident Annual	0.00
Dividend Yield	0%